Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 1/20 | 1.00 |
| ▸ | GRIN2C | Q14957 | 1/20 | 1.00 |
| ▸ | JAK3 | P52333 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
| ▸ | CDK4 | P11802 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zelquistinel SCHEMBL15936939 | 1.00 | GRIN2B (1.00) | GRIN2BGRIN2CJAK3TSHRKDM1A | |
| Zelquistinel SCHEMBL18325961 | 1.00 | GRIN2B (1.00) | GRIN2BGRIN2CJAK3TSHRKDM1A | |
| Zelquistinel SCHEMBL19628505 | 1.00 | GRIN2B (1.00) | GRIN2BGRIN2CJAK3TSHRKDM1A | |
| Zelquistinel SCHEMBL19628501 | 1.00 | GRIN2B (1.00) | GRIN2BGRIN2CJAK3TSHRKDM1A | |
| Zelquistinel SCHEMBL19629083 | 1.00 | GRIN2B (1.00) | GRIN2BGRIN2CJAK3TSHRKDM1A | |
| Zelquistinel SCHEMBL29880395 | 0.99 | GRIN2B (0.98) | GRIN2BGRIN2CJAK3TSHR | |
| SCHEMBL27336566 | 0.97 | GRIN2B (0.94) | GRIN2BGRIN2CJAK3TSHR | |
| SCHEMBL17712368 | 0.92 | GRIN2B (0.85) | GRIN2BGRIN2CJAK3KDM1ACDK4 | |
| SCHEMBL24339067 | 0.91 | GRIN2B (0.84) | GRIN2BGRIN2CJAK3TSHRKDM1A | |
| SCHEMBL19614955 | 0.90 | GRIN2B (0.82) | GRIN2BGRIN2CJAK3TSHRCDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220259217-A1 | PROCESSES AND INTERMEDIATES FOR PRODUCING DIAZASPIRO LACTAM COMPOUNDS | INNOVIVA TRC HOLDINGS LLC | 2022-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220259217-A1 | PROCESSES AND INTERMEDIATES FOR PRODUCING DIAZASPIRO LACTAM COMPOUNDS | DDO, DHPS, PGLS | GRIN2B 1870/4885GRIN2C 1817/4885JAK3 4630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.